|
|
|
|
|
|
Sponsors and Collaborators: |
University of Pittsburgh VA Pittsburgh Healthcare System American Society for Gastrointestinal Endoscopy |
Information provided by: | University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT00222898 |
The purpose of this study is to assist with early and accurate diagnosis of cancer in pancreatic cysts based on the analysis of DNA obtained by endoscopic ultrasound guided fine needle aspiration
Condition | Intervention |
Pancreatic Cyst Pancreatic Pseudocyst Pancreatic Neoplasm |
Procedure: DNA analysis of pancreatic cyst fluid / buccal swab |
MedlinePlus related topics: | Cancer Pancreatic Cancer |
Study Type: | Observational |
Study Design: | Screening, Longitudinal, Defined Population, Retrospective/Prospective Study |
Official Title: | Pancreatic Cyst DNA Analysis |
Estimated Enrollment: | 300 |
Study Start Date: | June 2004 |
The study of pancreatic diseases is hindered by the organ's deep seated location and especially lack of symptoms during the early stages of disease development and progression e.g. pancreatic cancer. This is particularly true of pancreatic cysts, the variety and the malignant potential of which encompass a broad spectrum. The radiological features distinguishing a benign from a pre-malignant to a frankly malignant cyst in the pancreas are frequently underwhelming and have lead to the clinical practice of sampling all but the most obvious. The yield of the aspirate in turn is frequently not of a quality upon which a clinical decision can be based.
Most would agree that the best approach for management of pancreatic cystic neoplasm lies in early diagnosis, ideally at a precancerous stage. The effectiveness and applicability of this study is the based on the ability of the cyst DNA analysis to stratify the patients at risk of developing pancreatic cancer based on the extent of accumulated mutational damage.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Indiana | |||||
Indiana University - Purdue University Indianapolis | |||||
Indianapolis, Indiana, United States, 46202 | |||||
United States, Massachusetts | |||||
Partners HealthCare System | |||||
Boston, Massachusetts, United States, 02114 | |||||
United States, Missouri | |||||
Washington University Medical Center | |||||
St. Louis, Missouri, United States, 63110 | |||||
United States, Pennsylvania | |||||
University of Pittsburgh | |||||
Pittsburgh, Pennsylvania, United States, 15213 | |||||
University of Pennsylvania | |||||
Philadelphia, Pennsylvania, United States, 19104 | |||||
VA Pittsburgh Healthcare System | |||||
Pittsburgh, Pennsylvania, United States, 15240 | |||||
United States, South Carolina | |||||
Medical University of South Carolina | |||||
Charleston, South Carolina, United States, 29425 |
University of Pittsburgh |
VA Pittsburgh Healthcare System |
American Society for Gastrointestinal Endoscopy |
Principal Investigator: | Asif Khalid, MD | University of Pittsburgh |
Study ID Numbers: | PANDA |
First Received: | September 20, 2005 |
Last Updated: | February 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00222898 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|